Publications by authors named "S Metivier"
Background And Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for treatment of compensated chronic hepatitis due to Delta virus (HDV) infection, however real-life data in large cohorts of patients with cirrhosis are lacking.
Methods: Consecutive HDV-infected patients with cirrhosis starting BLV 2 mg/day since September 2019 were included in a European retrospective multicenter real-life study (SAVE-D). Patient characteristics before and during BLV treatment were collected.
Background: Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%.
Methods And Results: Here we evaluated sustained virological response at week 12 post-treatment (SVR12) in 147 HCV-GT-5 patients from 14 French university hospitals (2014-2021) treated with direct-acting antivirals (DAA) in real-life.
Article Synopsis
- Bulevirtide is a new antiviral therapy specifically designed to treat chronic hepatitis D, and researchers aimed to understand its effectiveness alone and in combination with pegylated-interferon (Peg-IFN).
- Mathematical modeling of data from 183 patients showed that bulevirtide effectively blocks cell infection by 90.3%, while Peg-IFN blocks viral production at 92.4%, leading to enhanced outcomes when combined.
- Results indicated that combining bulevirtide with Peg-IFN resulted in a higher rate of viral decline and a better chance of achieving a cure, suggesting the need for further randomized clinical trials to assess treatment effectiveness.
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfection.
Methods: Patients received BLV 2 mg ± pegylated interferon-α (pegIFNα) according to the physician's decision.
Background: In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensated cirrhosis following treatment or not with direct antiviral agents from the French ANRS CO22 HEPATHER cohort.
Methods: We identified HCV patients who had experienced an episode of decompensated cirrhosis.